

Aiforia Technologies Plc Company release December 22, 2023 09:00 a.m.
EET

Share subscriptions based on stock options 2016A

Aiforia Technologies Plc, Company release, December 22, 2023 09:00 a.m.
EET

A total of 5,000 Aiforia Technologies Plc's new shares has been subscribed for with the Stock Options 2016A on November 21, 2023.

For subscriptions made with the stock options 2016A the entire subscription price of EUR 100.00 will be entered in the reserve for invested unrestricted equity. After the trade registration the total amount of shares is 25,950,616.

The shares subscribed for under the stock options 2016A have been registered in the Trade Register on December 22, 2023, as of which date the new shares will establish shareholder rights.

The shares will be traded in the Nasdaq Helsinki Plc's First North Growth Market Finland -marketplace as an additional lot with the company's old shares as of December 27, 2023.

The terms and conditions of stock options are available on the company's website at <https://investors.aiforia.com/>.

Further inquiries

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358405009878
<https://investors.aiforia.com/>

Certified Adviser

UB Securities Ltd
ubs@unitedbankers.fi

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate

diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com